Seattle Genetics Gross Profit 2006-2019 | SGEN

Seattle Genetics annual/quarterly gross profit history and growth rate from 2006 to 2019. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Seattle Genetics gross profit for the quarter ending June 30, 2019 was $0.208B, a 37.57% increase year-over-year.
  • Seattle Genetics gross profit for the twelve months ending June 30, 2019 was $0.683B, a 33.75% increase year-over-year.
  • Seattle Genetics annual gross profit for 2018 was $0.566B, a 32.3% increase from 2017.
  • Seattle Genetics annual gross profit for 2017 was $0.428B, a 13.92% increase from 2016.
  • Seattle Genetics annual gross profit for 2016 was $0.376B, a 25.54% increase from 2015.
Seattle Genetics Annual Gross Profit
(Millions of US $)
2018 $566
2017 $428
2016 $376
2015 $299
2014 $258
2013 $248
2012 $197
2011 $92
2010 $107
2009 $52
2008 $35
2007 $22
2006 $10
2005 $10
Seattle Genetics Quarterly Gross Profit
(Millions of US $)
Q2 2019 $208
Q1 2019 $185
Q4 2018 $139
Q3 2018 $152
Q2 2018 $151
Q1 2018 $125
Q4 2017 $114
Q3 2017 $121
Q2 2017 $96
Q1 2017 $97
Q4 2016 $94
Q3 2016 $95
Q2 2016 $85
Q1 2016 $102
Q4 2015 $83
Q3 2015 $74
Q2 2015 $69
Q1 2015 $74
Q4 2014 $66
Q3 2014 $68
Q2 2014 $62
Q1 2014 $62
Q4 2013 $61
Q3 2013 $66
Q2 2013 $69
Q1 2013 $53
Q4 2012 $60
Q3 2012 $46
Q2 2012 $45
Q1 2012 $45
Q4 2011 $46
Q3 2011 $20
Q2 2011 $13
Q1 2011 $12
Q4 2010 $8
Q3 2010 $16
Q2 2010 $37
Q1 2010 $46
Q4 2009 $22
Q3 2009 $12
Q2 2009 $9
Q1 2009 $9
Q4 2008 $10
Q3 2008 $8
Q2 2008 $10
Q1 2008 $7
Q4 2007 $8
Q3 2007 $5
Q2 2007 $6
Q1 2007 $4
Q4 2006 $3
Q3 2006 $2
Q2 2006 $3
Q1 2006 $2
Q4 2005 $2
Q3 2005 $3
Q2 2005 $2
Q1 2005 $3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $12.140B $0.655B
Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, ADCETRIS? (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME and ASG-15ME.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $108.806B 12.30
Gilead Sciences (GILD) United States $82.919B 10.07
Celgene (CELG) United States $63.614B 10.78
Biogen (BIIB) United States $44.842B 8.51
Vertex Pharmaceuticals (VRTX) United States $44.598B 53.91
Illumina (ILMN) United States $43.100B 49.95
CSL (CSLLY) Australia $35.794B 0.00
Regeneron Pharmaceuticals (REGN) United States $32.576B 15.31
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $27.088B 15.33
Incyte (INCY) United States $17.271B 70.04
Exact Sciences (EXAS) United States $14.835B 0.00
BioMarin Pharmaceutical (BMRN) United States $14.607B 0.00
SINO PHARMACEUT (SBMFF) China $14.154B 0.00
Sarepta Therapeutics (SRPT) United States $11.068B 0.00
Genmab (GNMSF) Denmark $11.046B 56.15
Array BioPharma (ARRY) United States $10.373B 0.00
Galapagos (GLPG) Belgium $9.396B 0.00
Bio-Rad Laboratories (BIO.B) United States $9.283B 49.21
QIAGEN (QGEN) Netherlands $8.917B 29.29
Guardant Health (GH) United States $8.158B 0.00
Alnylam Pharmaceuticals (ALNY) United States $8.030B 0.00
Bio-Techne Corp (TECH) United States $7.933B 54.13
Bluebird Bio (BLUE) United States $7.614B 0.00
Exelixis (EXEL) United States $6.419B 16.36
Amarin (AMRN) Ireland $5.979B 0.00
BeiGene (BGNE) Cayman Islands $5.801B 0.00
Ascendis Pharma (ASND) Denmark $4.841B 0.00
Blueprint Medicines (BPMC) United States $4.775B 0.00
ARGENX SE-ADR (ARGX) Netherlands $4.762B 0.00
Moderna (MRNA) United States $4.642B 0.00
Horizon Pharma Public (HZNP) Ireland $4.456B 11.48
Repligen (RGEN) United States $4.099B 102.12
Mirati Therapeutics (MRTX) United States $3.821B 0.00
Spark Therapeutics (ONCE) United States $3.720B 0.00
ACADIA Pharmaceuticals (ACAD) United States $3.705B 0.00
China Biologic Products (CBPO) China $3.661B 23.25
Alkermes (ALKS) Ireland $3.651B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.569B 0.00
MorphoSys AG (MOR) Germany $3.528B 0.00
Arena Pharmaceuticals (ARNA) United States $3.064B 6.23
Amicus Therapeutics (FOLD) United States $2.934B 0.00
Immunomedics (IMMU) United States $2.860B 0.00
UniQure (QURE) Netherlands $2.736B 0.00
Medicines (MDCO) United States $2.670B 0.00
Reata Pharmaceuticals (RETA) United States $2.620B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.595B 0.00
MyoKardia (MYOK) United States $2.466B 0.00
Halozyme Therapeutics (HALO) United States $2.370B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $2.357B 0.00
NeoGenomics (NEO) United States $2.277B 149.06
Emergent Biosolutions (EBS) United States $2.269B 19.71
Ligand Pharmaceuticals (LGND) United States $2.233B 18.49
Acceleron Pharma (XLRN) United States $2.230B 0.00
Myriad Genetics (MYGN) United States $2.092B 20.81
Genomic Health (GHDX) United States $2.075B 44.07
Zai Lab (ZLAB) China $2.068B 0.00
Intercept Pharmaceuticals (ICPT) United States $2.044B 0.00
Akcea Therapeutics (AKCA) United States $2.041B 0.00
Denali Therapeutics (DNLI) United States $1.988B 0.00
REGENXBIO (RGNX) United States $1.800B 0.00
Insmed (INSM) United States $1.720B 0.00
Cambrex (CBM) United States $1.514B 19.15
AnaptysBio (ANAB) United States $1.474B 0.00
RA PHARMCTL INC (RARX) United States $1.418B 0.00
Fate Therapeutics (FATE) United States $1.393B 0.00
Innoviva (INVA) United States $1.361B 3.76
Sangamo Therapeutics (SGMO) United States $1.338B 0.00
Alector (ALEC) United States $1.298B 0.00
Athenex (ATNX) United States $1.278B 0.00
Coherus BioSciences (CHRS) United States $1.226B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.185B 0.00
Editas Medicine (EDIT) United States $1.174B 0.00
Epizyme (EPZM) United States $1.156B 0.00
Dicerna Pharmaceuticals (DRNA) United States $1.032B 0.00
Cara Therapeutics (CARA) United States $1.030B 0.00
Codexis (CDXS) United States $1.011B 0.00
Twist Bioscience (TWST) United States $0.982B 0.00
ANI Pharmaceuticals (ANIP) United States $0.973B 17.25
Zymeworks (ZYME) Canada $0.952B 0.00
Momenta Pharmaceuticals (MNTA) United States $0.947B 0.00
Principia Biopharma (PRNB) United States $0.921B 0.00
Adverum Biotechnologies (ADVM) United States $0.891B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.884B 0.00
Retrophin (RTRX) United States $0.879B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.856B 0.00
Vericel (VCEL) United States $0.822B 0.00
Alder BioPharmaceuticals (ALDR) United States $0.820B 0.00
WAVE Life Sciences (WVE) Singapore $0.794B 0.00
Arvinas (ARVN) United States $0.789B 0.00
Intellia Therapeutics (NTLA) United States $0.782B 0.00
Precision BioSciences (DTIL) United States $0.701B 0.00
Zealand Pharma (ZEAL) Denmark $0.692B 8.08
Vanda Pharmaceuticals (VNDA) United States $0.688B 32.47
Zealand Pharma (ZLDPF) Denmark $0.683B 0.00
Intra-Cellular Therapies (ITCI) United States $0.652B 0.00
Cytokineticsorporated (CYTK) United States $0.643B 0.00
Cellectis S.A (CLLS) France $0.634B 0.00
Heska (HSKA) United States $0.622B 63.66
Autolus Therapeutics (AUTL) United Kingdom $0.612B 0.00
DBV Technologies S.A (DBVT) France $0.600B 0.00
Stemline Therapeutics (STML) United States $0.588B 0.00
Clovis Oncology (CLVS) United States $0.580B 0.00
Anika Therapeutics (ANIK) United States $0.577B 19.72
Lexicon Pharmaceuticals (LXRX) United States $0.561B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.560B 0.00
Revance Therapeutics (RVNC) United States $0.554B 0.00
CytomX Therapeutics (CTMX) United States $0.527B 0.00
Pharming Group (PHGUF) Netherlands $0.521B 0.00
MiMedx (MDXG) United States $0.503B 0.00
Mesoblast (MESO) Australia $0.494B 0.00
PHARMA MAR SA (PHMMF) Spain $0.452B 0.00
UROGEN PHARMA (URGN) United States $0.438B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.437B 0.00
Puma Biotechnology (PBYI) United States $0.394B 0.00
Prothena (PRTA) Ireland $0.393B 0.00
AC Immune SA (ACIU) Switzerland $0.378B 24.35
PDL BioPharma (PDLI) United States $0.376B 8.97
Biofrontera AG (BFRA) Germany $0.373B 0.00
Sinovac Biotech (SVA) China $0.371B 0.00
Arcus Biosciences (RCUS) United States $0.364B 0.00
Gritstone Oncology (GRTS) United States $0.361B 0.00
Starpharma Holdings (SPHRY) Australia $0.360B 0.00
Bellus Health (BLUSF) Canada $0.358B 0.00
Scholar Rock Holding (SRRK) United States $0.345B 0.00
Avid Bioservices (CDMO) United States $0.343B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.342B 0.00
Merus (MRUS) Netherlands $0.341B 0.00
BioDelivery Sciences (BDSI) United States $0.341B 0.00
Albireo Pharma (ALBO) United States $0.340B 0.00
Acorda Therapeutics (ACOR) United States $0.332B 5.85
Agenus (AGEN) United States $0.330B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.330B 0.00
Prometic Life Sciences (PFSCD) Canada $0.322B 0.00
Kadmon Holdings (KDMN) United States $0.321B 0.00
Theratechnologies (THERF) Canada $0.320B 0.00
Sorrento Therapeutics (SRNE) United States $0.319B 0.00
Syros Pharmaceuticals (SYRS) United States $0.314B 0.00
Protagonist Therapeutics (PTGX) United States $0.307B 0.00
Senesco Technologies (ELOX) United States $0.297B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.295B 0.00
Cellular Biomedicine (CBMG) United States $0.277B 0.00
Inovio Pharmaceuticals (INO) United States $0.274B 0.00
Kindred Biosciences (KIN) United States $0.264B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.258B 0.00
Sutro Biopharma (STRO) United States $0.256B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.246B 0.00
PHASEBIO PHARMA (PHAS) United States $0.246B 0.00
ChromaDex (CDXC) United States $0.245B 0.00
Kamada (KMDA) Israel $0.239B 9.28
Dynavax Technologies (DVAX) United States $0.238B 0.00
Geron (GERN) United States $0.229B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.225B 0.00
ADMA Biologics Inc (ADMA) United States $0.224B 0.00
Athersys (ATHX) United States $0.213B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.202B 0.00
Five Prime Therapeutics (FPRX) United States $0.202B 0.00
MannKind (MNKD) United States $0.201B 0.00
Mersana Therapeutics (MRSN) United States $0.200B 0.00
Cerecor (CERC) United States $0.197B 0.00
Affimed (AFMD) Germany $0.193B 0.00
OSMOTICA PHARM (OSMT) United States $0.184B 0.00
POXEL SA FRANCE (PXXLF) $0.184B 0.00
Abeona Therapeutics (ABEO) United States $0.184B 0.00
Synlogic (SYBX) United States $0.179B 0.00
Enzo Biochem (ENZ) United States $0.174B 0.00
Spero Therapeutics (SPRO) United States $0.174B 0.00
Compugen (CGEN) Israel $0.172B 0.00
Arsanis (XFOR) United States $0.168B 0.00
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
XOMA (XOMA) United States $0.165B 0.00
Nicox SA (NICXF) France $0.161B 0.00
Cue Biopharma (CUE) United States $0.157B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.156B 0.00
Strongbridge Biopharma (SBBP) United States $0.150B 8.66
Liquidia Technologies (LQDA) United States $0.144B 0.00
Celyad SA (CYAD) Belgium $0.142B 0.00
Alcobra (ARCT) United States $0.141B 0.00
OvaScience (MLND) United States $0.141B 0.00
Adocia (ADOCY) France $0.140B 0.00
Windtree Therapeutics (WINT) United States $0.138B 0.00
Dyadic (DYAI) United States $0.136B 0.00
TOCAGEN INC (TOCA) United States $0.135B 0.00
Northwest Biotherapeutics (NWBO) United States $0.130B 0.00
Seres Therapeutics (MCRB) United States $0.127B 0.00
Aptinyx (APTX) United States $0.125B 0.00
NantKwest (NK) United States $0.121B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.114B 0.00
Aduro Biotech (ADRO) United States $0.114B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.110B 0.00
Novavax (NVAX) United States $0.108B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.108B 0.00
Verastem (VSTM) United States $0.106B 0.00
Checkpoint Therapeutics (CKPT) United States $0.104B 0.00
Menlo Therapeutics (MNLO) United States $0.103B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.103B 0.00
Catalyst Biosciences (CBIO) United States $0.099B 0.00
Arbutus Biopharma (ABUS) Canada $0.098B 0.00
SESEN BIO, INC (SESN) United States $0.098B 0.00
Trevena (TRVN) United States $0.094B 0.00
Fortress Biotech (FBIO) United States $0.089B 0.00
Pluristem Therapeutics (PSTI) Israel $0.088B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.087B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.084B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.082B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.080B 0.00
Unum Therapeutics (UMRX) United States $0.079B 0.00
VBI Vaccines (VBIV) United States $0.079B 0.00
AquaBounty Technologies (AQB) United States $0.078B 0.00
Curis (CRIS) United States $0.076B 0.00
Selecta Biosciences (SELB) United States $0.076B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.071B 0.00
Idera Pharmaceuticals (IDRA) United States $0.071B 0.00
Applied Genetic Technologies (AGTC) United States $0.071B 38.80
VTv Therapeutics (VTVT) United States $0.070B 0.00
Signal Genetics (MGEN) United States $0.070B 0.00
Orgenesis (ORGS) United States $0.067B 0.00
Oncobiologics (OTLK) United States $0.064B 0.00
Alimera Sciences (ALIM) United States $0.062B 0.00
Antibe Therapeutics (ATBPF) Canada $0.061B 0.00
ARAVIVE, INC (ARAV) United States $0.060B 0.00
NewLink Genetics (NLNK) United States $0.060B 0.00
Organovo Holdings (ONVO) United States $0.060B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.058B 0.00
Prima BioMed (IMMP) Australia $0.057B 0.00
AIT Therapeutics (XAIR) United States $0.057B 0.00